Oestrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin-1

Related Experiment Video

Updated: Oct 2, 2026

In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

T-M Lee1, S-F Su, C-H Tsai

  • 1National Taiwan University Hospital, 7 Chung-Shan S. Road, Taipei, Taiwan 10002.

European Journal of Clinical Investigation
|March 16, 2002
PubMed

Insights

Endothelin-1 is released after coronary angioplasty, causing vasoconstriction. Oestrogen administration reduces endothelin-1 levels, thereby attenuating this effect and offering a new treatment strategy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Interventional Cardiology

Background:

  • Controversy exists regarding endothelin-1 release post-coronary angioplasty.
  • Endothelin-1 is a potent vasoconstrictor implicated in cardiovascular events.

Purpose of the Study:

  • To determine if endothelin-1 is released after coronary angioplasty.
  • To investigate if oestrogen reduces endothelin-1 concentrations and affects coronary vasomotor tone.

Main Methods:

  • Prospective study of 24 patients undergoing elective coronary angioplasty.
  • Randomization into two groups: no oestrogen (n=12) and intracoronary oestrogen (n=12).
  • Quantitative coronary angiography and simultaneous blood sampling from aorta and coronary sinus before and after angioplasty.

Main Results:

  • Coronary artery diameters significantly reduced 15 min post-angioplasty in the control group.
  • Vasoconstriction was blunted in the oestrogen-treated group.
  • Endothelin-1 levels increased significantly post-angioplasty in controls, an effect attenuated by oestrogen; a correlation between vasomotion and endothelin-1 was observed.

Conclusions:

  • Endothelin-1 is released into the coronary circulation post-angioplasty, contributing to vasoconstriction.
  • Oestrogen attenuates post-angioplasty vasoconstriction by reducing endothelin-1 levels.
  • This suggests a potential therapeutic strategy for managing coronary vasoconstriction after angioplasty.
Abstract

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...